


SUPPLEMENTARY DATA

Figure 1 of the supplementary data. Flowchart of the study cohort.



DCM, dilated cardiomyopathy. * In 3 women, DCM diagnosis was established at the end of their first pregnancy, all with heart failure symptoms. Adverse cardiac events were defined as any of the following: HF symptoms requiring the use of intravenous diuretics, sustained ventricular tachycardia (SVT), appropriate implantable cardioverter-defibrillator (ICD) shock, left ventricular assist device (LVAD) implantation, heart transplant, and maternal cardiac death during pregnancy, or labor and delivery, and up to 6 months postpartum.

Table 1 of the supplementary data. DCM-associated variants identified in 48 women

Gene	Nucleotide Change	Amino Acid Change	No.
BAG3	c.508_1728del	Deletion of exons 3 and 4	1
BAG3	c.1353C>A	p.Tyr451*	3
BAG3	c.382_383insAG	p.Ala128GluFs*84	1
BAG3	c.1360G>A	p.Glu455Lys	1
DMD	c.7099-9829_7543-1206del	p.Glu2367_Lys2514del	1
DSP	c.7773_7776del	p.Ser2591Argfs*11	1
DSP	c.7139delC	p.Pro2380Glnfs*11	1
DSP	c.1891C>T	p.Gln631*	1
DSP	c.2390_2393delTCTG	p.val797Alafs*14	1
DSP	c.3640_3641delAT	p.Ile1214*	1
LMNA	c.575A>G	p.Asp192Gly	1
LMNA	c.1292C>G	p.Ser431*	1
LMNA	c.1526CdupC	p.Thr510Tyrfs*42	1
LMNA	c.961C>T	p.Arg321*	1
LMNA	c.1130G>A	p.Arg377His	1
LMNA	c.240delC	p.Tyr81Thrfs*15	1
MYBPC3	c.2512G>C	p.Glu838Gln	1
MYH7	c.2729A>G	p.Lys910Arg	1
MYH7	c.1106G>A	p.Arg369Gln	2
MYH7	c.4333A>G	p.Lys1445Glu	1
RBM20	c.1900C>T	p.Arg634Trp	1
RBM20	c.1913C>T	p.Pro638Leu	1
RBM20	c.2283delG	p.Arg761?	1
RBM20	c.2731G>A	p.Val911Met	1
SCN5A	c.253G>A	p.Leu828Phe	1
TPM1	c.337C>G	p.Leu113Val	1
TNNT2	c.416G>A	p.Arg139His	1
TTN	c.25655C>A	p.Ser8552*	1
TTN	c.70497_40498insT	p.Leu23499fs	1
TTN	c.4824_0G>A	p.Trp16080*	1
TTN	c.59365delG	p.Val19789Cysfs*4	1
TTN	c.67813C>T	p.Arg22605*	1
TTN	c.52699delG	p.Glu17567Asnfs*12	1
TTN	c.11655_11656delAA	p.Arg3886fs*20	3
TTN	c.53704_53705del	p.Val17902fs	2
TTN	c.80790delG	p.Trp26930Cysfs*16	1
TTN	c.12107delC	p.4036Glnfs*14	1
TTN	c.73377delT	p.Arg24461GluFs*18	1
TTN	c.89273A>T	p.Lys26425	1
TTN	c.66086delG	p.Gly22029GluFs*22	1
TTN	c.64417dupG	p.Val21473Gly?	1
TTN	c.82608delT	p. Gly27537Alafs*43	1

DCM, dilated cardiomyopathy

Table 2 of the supplementary data

Obstetric and fetal outcomes

	Pregnancies, No. (%)		P
	DCM (n = 48)	Healthy carriers (n = 35)	
<i>Obstetric complications</i>			
Total events	5 (10)	1 (3)	.38
Postpartum hemorrhage	4 (8)	1 (3)	
Pre-eclampsia	1 (2)		
<i>Fetal and/or neonatal complications</i>			
Total events	5 (10)	1 (3)	.38
Preterm birth (< 37 wks gestation)	4 (8) ^a		
Low birthweight (less than 2500 g)		1 (3) ^b	
Very low birthweight (less than 1500 g)	1 (2)		

Each pregnancy corresponded to a single woman.

^a In 2 cases due to heart failure symptoms and in 2 due to fetal causes.

^b Patient also had pre-eclampsia.

Table 3 of the supplementary data

Characteristics of healthy carriers prior to the first pregnancy according to the diagnosis of DCM during follow-up

	DCM occurrence after pregnancy		P
	Yes (n = 6)	No (n = 12)	
<i>Age at first delivery, y</i>	27 ± 2.7	29 ± 3.6	.32
<i>Pregnancies* - (mean [range])</i>	1.8 [1-4]	1.8 [1-4]	.96
<i>TTNtv</i>	3 (50)	6 (50)	1
<i>LVEF at first evaluation, %</i>	57 ± 4.6	59 ± 8.3	.74
<i>LVEDD at first evaluation, mm</i>	49 ± 5.2	47 ± 3.2	.42
<i>Cardiac adverse event before first pregnancy</i>	4 (67)	0	.06
<i>Treatment withdrawal</i>	5 (83)	3 (50)	.54

* Spontaneous abortions were not included in the total number of pregnancies.

Table 4 of the supplementary data

Dilated cardiomyopathy causing genes included in genetic analyses

<p>ABCC9, ACTC1, ALMS1, ANKRD1, BAG3, CAV3, CRYAB, CSRP3, DES, DMD, DNAJC19, DSG2, DSP, DTNA, EMD, EYA4, FKRP, FKTN, FXN, HADHA, HFE, ILK, LAMA2, LAMA4, LAMP2, LDB3, LMNA, MYBPC3, MYH6, MYH7, NEXN, PDLIM3, PLN, RBM20, SCN5A, SDHA, SGCB, SGCD, SGCG, TAZ, TBX20, TCAP, TMPO, TNNC1, TNNI3, TNNT2, TPM1, TTN, VCL</p>
--

List of countries participating in this cohort:

European countries: Spain, Poland, Czech Republic, United Kingdom, Italy, Romania, Netherlands, Denmark

Oceania: Australia

Additional investigators from participating centers:

Unit for Screening Studies in Inherited Cardiovascular Diseases. National Institute of Cardiology, Warsaw

Zofia Bilinska, MD, PhD

Department of Medical Genetics, Warsaw Medical University

Prof. Rafal Ploski, MD, PhD

Institute of Cardiovascular Science, University College London, Gower St, London WC1E 6BT, UK.

St. Bartholomew's Hospital, Barts Heart Centre, Barts Health NHS Trust, Whitechapel Rd, London E1 1BB, UK

Professor Perry Elliott

Centre for Heart Muscle Disease, Institute of Cardiovascular Science, University College London, London, United Kingdom

Petros Syrris, MD, PhD

University College London and Barts Heart Centre, London, UK

Douglas Ewan Cannie, MD